OASM vs. NBSE, PRFX, GRI, ATNF, GLMD, PBLA, DRMA, CMRA, INM, and BDRX
Should you be buying Oasmia Pharmaceutical AB (publ) stock or one of its competitors? The main competitors of Oasmia Pharmaceutical AB (publ) include NeuBase Therapeutics (NBSE), PainReform (PRFX), GRI Bio (GRI), 180 Life Sciences (ATNF), Galmed Pharmaceuticals (GLMD), Panbela Therapeutics (PBLA), Dermata Therapeutics (DRMA), Comera Life Sciences (CMRA), InMed Pharmaceuticals (INM), and Biodexa Pharmaceuticals (BDRX). These companies are all part of the "medical" sector.
NeuBase Therapeutics (NASDAQ:NBSE) and Oasmia Pharmaceutical AB (publ) (NASDAQ:OASM) are both small-cap medical companies, but which is the better investment? We will contrast the two companies based on the strength of their dividends, institutional ownership, valuation, community ranking, profitability, earnings, risk, analyst recommendations and media sentiment.
NeuBase Therapeutics has a net margin of 0.00% compared to NeuBase Therapeutics' net margin of -8,633.64%. NeuBase Therapeutics' return on equity of -43.94% beat Oasmia Pharmaceutical AB (publ)'s return on equity.
In the previous week, NeuBase Therapeutics had 1 more articles in the media than Oasmia Pharmaceutical AB (publ). MarketBeat recorded 1 mentions for NeuBase Therapeutics and 0 mentions for Oasmia Pharmaceutical AB (publ). Oasmia Pharmaceutical AB (publ)'s average media sentiment score of 0.00 equaled NeuBase Therapeutics'average media sentiment score.
NeuBase Therapeutics has higher earnings, but lower revenue than Oasmia Pharmaceutical AB (publ).
12.4% of NeuBase Therapeutics shares are owned by institutional investors. Comparatively, 0.1% of Oasmia Pharmaceutical AB (publ) shares are owned by institutional investors. 13.9% of NeuBase Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company will outperform the market over the long term.
Oasmia Pharmaceutical AB (publ) received 77 more outperform votes than NeuBase Therapeutics when rated by MarketBeat users. Likewise, 65.97% of users gave Oasmia Pharmaceutical AB (publ) an outperform vote while only 60.49% of users gave NeuBase Therapeutics an outperform vote.
NeuBase Therapeutics has a beta of 0.83, suggesting that its stock price is 17% less volatile than the S&P 500. Comparatively, Oasmia Pharmaceutical AB (publ) has a beta of 0.96, suggesting that its stock price is 4% less volatile than the S&P 500.
Summary
Oasmia Pharmaceutical AB (publ) beats NeuBase Therapeutics on 6 of the 11 factors compared between the two stocks.
Get Oasmia Pharmaceutical AB (publ) News Delivered to You Automatically
Sign up to receive the latest news and ratings for OASM and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding OASM and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Oasmia Pharmaceutical AB (publ) Competitors List
Related Companies and Tools
